Global X China Biotech ETF (02820.HK) Rises 2.55% in Afternoon Trading as Drug Price Governance Officially Enters New Phase

NewTimeSpace News–On April 15, 2026, Global X China Biotech ETF (02820.HK) strengthened in afternoon trading. As of 13:47, the latest quote was 74.04 HKD, up 2.55%.

NewTimeSpace News has learned that Global X China Biotech ETF (02820.HK) tracks the Solactive China Biotech Index, employing free-float market capitalization weighting to cover 37 Chinese biotech companies spanning A-shares, H-shares, and US-listed stocks. With heavy positions in Wuxi AppTec series, Hengrui Medicine, BeiGene, and other innovative drug and CXO leaders, it serves as a high-volatility growth tool for capturing China's biopharmaceutical industry upgrading and globalization dividends.

On the news front, on April 15, 2026, the General Office of the State Council issued "Several Opinions on Improving the Drug Price Formation Mechanism," emphasizing the full play of the market's decisive role in resource allocation, better government role, effective service to the unified national market construction in the pharmaceutical sector, improvement of the market-oriented drug price formation mechanism, support for high-quality development of the pharmaceutical industry, and ensuring that the people have access to high-quality and affordable medicines.

CMB International Securities noted that Document No. 9 is the most systematic and comprehensive top-level design document in the drug price field since the establishment of the National Healthcare Security Administration, marking the official transition of China's drug price governance to a new phase of "market dominance, classified management, and full-chain value governance." The policy orientation encourages genuine pharmaceutical innovation through reasonable price return mechanisms and improves accessibility through a multi-level payment system, clearly benefiting the innovative development of the pharmaceutical industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.